MUNICH – “This is very important from a public health policy perspective.” – Dr. Robert S. Rosenman
Rivaroxaban (Xarelto) is the first direct oral anticoagulant to gain an indication for prevention of cardiovascular events.
Cardiologists and pulmonologists should collaborate to better identify the relationship between lung function decline and early CV disease...
And HIV infection may double patients’ stroke rate.
New study looks at the effects of combining clopidogrel and aspirin on risk of new stroke or cardiologic event soon after the...
Creation of electronic health record order sets may improve adherence to The Joint Commission National Quality Measures for care of veterans with...
ATLAS reanalysis shows rivaroxaban in a different light; cerebral protection may be best for all TAVRs; and more in MDedge Cardiocast.
Stroke patients may benefit from endovascular thrombectomy later than previously believed.
New data show that stroke deaths are increasing and happening to a much younger demographic.
FDA approves nonsurgical Amplatzer PFO Occluder to close a patent foramen ovale and reduce the risk of stroke.